Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization-a correlative study with urine PCA3 and TMPRSS2-ERG

Joshua I. Warrick; Scott A. Tomlins; Shannon L. Carskadon; Allison M. Young; Javed Siddiqui; John T. Wei; Arul M. Chinnaiyan; Lakshmi P. Kunju; Nallasivam Palanisamy

doi:10.1038/modpathol.2013.169

Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization-a correlative study with urine PCA3 and TMPRSS2-ERG

Joshua I. Warrick
, Scott A. Tomlins
, Shannon L. Carskadon
, Allison M. Young
, Javed Siddiqui
, John T. Wei
, Arul M. Chinnaiyan
, Lakshmi P. Kunju
, Nallasivam Palanisamy

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

PCA3 is a prostate-specific non-coding RNA, with utility as a urine-based early detection biomarker. Here, we report the evaluation of tissue PCA3 expression by RNA in situ hybridization in a cohort of 41 mapped prostatectomy specimens. We compared tissue PCA3 expression with tissue level ERG expression and matched pre-prostatectomy urine PCA3 and TMPRSS2-ERG levels. Across 136 slides containing 138 foci of prostate cancer, PCA3 was expressed in 55% of cancer foci and 71% of high-grade prostatic intraepithelial neoplasia foci. Overall, the specificity of tissue PCA3 was >90% for prostate cancer and high-grade prostatic intraepithelial neoplasia combined. Tissue PCA3 cancer expression was not significantly associated with urine PCA3 expression. PCA3 and ERG positivity in cancer foci was positively associated (P<0.01). We report the first comprehensive assessment of PCA3 expression in prostatectomy specimens, and find limited correlation between tissue PCA3 and matched urine in prostate cancer.

Original language	English (US)
Pages (from-to)	609-620
Number of pages	12
Journal	Modern Pathology
Volume	27
Issue number	4
DOIs	https://doi.org/10.1038/modpathol.2013.169
State	Published - Apr 2014

All Science Journal Classification (ASJC) codes

Pathology and Forensic Medicine

Access to Document

10.1038/modpathol.2013.169

Cite this

@article{9b1c2e1667a84697ad2fe1b134d69bc7,

title = "Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization-a correlative study with urine PCA3 and TMPRSS2-ERG",

abstract = "PCA3 is a prostate-specific non-coding RNA, with utility as a urine-based early detection biomarker. Here, we report the evaluation of tissue PCA3 expression by RNA in situ hybridization in a cohort of 41 mapped prostatectomy specimens. We compared tissue PCA3 expression with tissue level ERG expression and matched pre-prostatectomy urine PCA3 and TMPRSS2-ERG levels. Across 136 slides containing 138 foci of prostate cancer, PCA3 was expressed in 55\% of cancer foci and 71\% of high-grade prostatic intraepithelial neoplasia foci. Overall, the specificity of tissue PCA3 was >90\% for prostate cancer and high-grade prostatic intraepithelial neoplasia combined. Tissue PCA3 cancer expression was not significantly associated with urine PCA3 expression. PCA3 and ERG positivity in cancer foci was positively associated (P<0.01). We report the first comprehensive assessment of PCA3 expression in prostatectomy specimens, and find limited correlation between tissue PCA3 and matched urine in prostate cancer.",

author = "Warrick, \{Joshua I.\} and Tomlins, \{Scott A.\} and Carskadon, \{Shannon L.\} and Young, \{Allison M.\} and Javed Siddiqui and Wei, \{John T.\} and Chinnaiyan, \{Arul M.\} and Kunju, \{Lakshmi P.\} and Nallasivam Palanisamy",

note = "Funding Information: This work was supported in part by the US National Institutes of Health Early Detection Research Network (U01 CA111275 and U01 CA113913), NIH SPORE (P50 CA69568), and R01 CA132874. NP and SAT are supported by University of Michigan Prostate SPORE Career Development Awards. AMC is supported by the Howard Hughes Medical Institute, the Doris Duke Foundation, and the Prostate Cancer Foundation and is an American Cancer Research Professor and a Taubman Scholar. We would like to thank Angela Wu, Ritu Bhalla and Rohit Mehra for providing help and advice.",

year = "2014",

month = apr,

doi = "10.1038/modpathol.2013.169",

language = "English (US)",

volume = "27",

pages = "609--620",

journal = "Modern Pathology",

issn = "0893-3952",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization-a correlative study with urine PCA3 and TMPRSS2-ERG

AU - Warrick, Joshua I.

AU - Tomlins, Scott A.

AU - Carskadon, Shannon L.

AU - Young, Allison M.

AU - Siddiqui, Javed

AU - Wei, John T.

AU - Chinnaiyan, Arul M.

AU - Kunju, Lakshmi P.

AU - Palanisamy, Nallasivam

N1 - Funding Information: This work was supported in part by the US National Institutes of Health Early Detection Research Network (U01 CA111275 and U01 CA113913), NIH SPORE (P50 CA69568), and R01 CA132874. NP and SAT are supported by University of Michigan Prostate SPORE Career Development Awards. AMC is supported by the Howard Hughes Medical Institute, the Doris Duke Foundation, and the Prostate Cancer Foundation and is an American Cancer Research Professor and a Taubman Scholar. We would like to thank Angela Wu, Ritu Bhalla and Rohit Mehra for providing help and advice.

PY - 2014/4

Y1 - 2014/4

N2 - PCA3 is a prostate-specific non-coding RNA, with utility as a urine-based early detection biomarker. Here, we report the evaluation of tissue PCA3 expression by RNA in situ hybridization in a cohort of 41 mapped prostatectomy specimens. We compared tissue PCA3 expression with tissue level ERG expression and matched pre-prostatectomy urine PCA3 and TMPRSS2-ERG levels. Across 136 slides containing 138 foci of prostate cancer, PCA3 was expressed in 55% of cancer foci and 71% of high-grade prostatic intraepithelial neoplasia foci. Overall, the specificity of tissue PCA3 was >90% for prostate cancer and high-grade prostatic intraepithelial neoplasia combined. Tissue PCA3 cancer expression was not significantly associated with urine PCA3 expression. PCA3 and ERG positivity in cancer foci was positively associated (P<0.01). We report the first comprehensive assessment of PCA3 expression in prostatectomy specimens, and find limited correlation between tissue PCA3 and matched urine in prostate cancer.

AB - PCA3 is a prostate-specific non-coding RNA, with utility as a urine-based early detection biomarker. Here, we report the evaluation of tissue PCA3 expression by RNA in situ hybridization in a cohort of 41 mapped prostatectomy specimens. We compared tissue PCA3 expression with tissue level ERG expression and matched pre-prostatectomy urine PCA3 and TMPRSS2-ERG levels. Across 136 slides containing 138 foci of prostate cancer, PCA3 was expressed in 55% of cancer foci and 71% of high-grade prostatic intraepithelial neoplasia foci. Overall, the specificity of tissue PCA3 was >90% for prostate cancer and high-grade prostatic intraepithelial neoplasia combined. Tissue PCA3 cancer expression was not significantly associated with urine PCA3 expression. PCA3 and ERG positivity in cancer foci was positively associated (P<0.01). We report the first comprehensive assessment of PCA3 expression in prostatectomy specimens, and find limited correlation between tissue PCA3 and matched urine in prostate cancer.

UR - https://www.scopus.com/pages/publications/84897526502

UR - https://www.scopus.com/pages/publications/84897526502#tab=citedBy

U2 - 10.1038/modpathol.2013.169

DO - 10.1038/modpathol.2013.169

M3 - Article

C2 - 24072184

AN - SCOPUS:84897526502

SN - 0893-3952

VL - 27

SP - 609

EP - 620

JO - Modern Pathology

JF - Modern Pathology

IS - 4

ER -

Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization-a correlative study with urine PCA3 and TMPRSS2-ERG

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this